MENU
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2026 All rights reserved. Tickeron Inc.
ALLO
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Allogene Therapeutics (ALLO) Ownership - Who owns Allogene Therapeutics?

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases... Show more

Industry: #Biotechnology
#MovingAverage#Momentum#MACD#Pattern#RSI#Stochastic#Aroon#Bollinger

Profile

Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
152
Web
https://www.allogene.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
707.57M
P/E Ratio
N/A
Total Cash
266.89M
Projected Growth
N/A
Total Debt
72.63M
Revenue
N/A
Risk (Beta)
0.75
Dividend Yield
N/A
Total Cash/Share
0.77
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
ALLO
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
View AI-Driven Trading for ALLO
A.I. Advisor
published General Information

General Information

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology

Profile
Details
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
152
Web
https://www.allogene.com